Related Experiment Video
Updated: Dec 7, 2025
04:01
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
1.6K
Abnormal Ferroptosis in Myelodysplastic Syndrome
Qi Lv1, Haiyue Niu1, Lanzhu Yue1
1Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
Frontiers in Oncology
|September 28, 2020
Summary
Decitabine induces cell death in myelodysplastic syndrome (MDS) by promoting ferroptosis, a process involving iron, reduced glutathione (GSH), and lipid reactive oxygen species. This study clarifies the mechanism of ferroptosis in MDS.
Area of Science:
- Cell Death Mechanisms
- Iron Metabolism
- Oxidative Stress
Background:
- Ferroptosis is iron-dependent cell death linked to GPX4 inactivation and reactive oxygen species accumulation.
- The specific mechanisms of ferroptosis in myelodysplastic syndrome (MDS) remain largely unknown.
Purpose of the Study:
- To investigate the role and regulation of ferroptosis in myelodysplastic syndrome (MDS).
- To elucidate the impact of decitabine treatment on ferroptosis pathways in MDS.
Main Methods:
- Assays for cell viability, reactive oxygen species (ROS), glutathione (GSH), and GPX4 activity were conducted.
- Experiments utilized MDS cell lines, primary MDS cells, and iron overload mouse models.
Main Results:
- Decitabine treatment in MDS cells decreased GSH and GPX4 activity while increasing ROS, characteristic of ferroptosis.
- Ferrostatin-1 and DFO partially reversed decitabine's effects, indicating ferroptosis involvement.
- Iron overload in mice mirrored these changes, with reduced cell viability and altered redox balance.
Conclusions:
- Ferroptosis is a key mechanism underlying decitabine-induced cell death in MDS.
- Decitabine triggers ferroptosis by increasing ROS and reducing GSH levels and GPX4 activity in MDS cells.
